



**LONDON
STOCK
EXCHANGE**

An LSEG Business



RNS

Director/PDMR Shareholding



DIRECTOR DEALINGS

[GENFLOW BIOSCIENCES PLC](#)

Released 07:00:10 28 March 2025

RNS Number : 5924C
Genflow Biosciences PLC
28 March 2025

**THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE CO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGUL
NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPE
(WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEN
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN TI
DOMAIN.**

28 March 2025

Genflow Biosciences Plc

Director's Dealing

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") the or company listed in Europe, is pleased to announce that it has been notified that Dr. Eric Leire, Company, has today purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence open market.

Details of the transaction are set out below:

Name	Dr. Eric Leire
Position	Chief Executive Officer
Date of Purchase	27 March 2025
Number of Ordinary Shares Purchased	2,100,000

Name	Dr. Eric Leire
Price per Ordinary Share	1.15p
Total Consideration	£24,150
Nature of Transaction	Market purchase
Total Shareholding Following the Transaction	126,514,999
Interest in Ordinary Shares (percentage)	36.18%

NOTIFICATION AND PUBLIC DISCLOSURE OF A TRANSACTION BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

The following disclosure is made in accordance with the requirements of the UK Market Abuse Regulations. It provides details in relation to the purchase of Ordinary Shares by a Director:

1.	Details of the person discharging managerial responsibilities / person closely associated						
a)	Name	Eric Leire					
2.	Reason for the Notification						
a)	Position/status	PDMR					
b)	Initial notification / Amendment	Initial notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Genflow Biosciences Plc					
b)	LEI	213800HVOFXRXVEGDN62					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the Financial instrument, type of instrument Identification Code	Ordinary Shares of £0.0003 GB00BP2C3V08					
b)	Nature of the transaction	Issue of ordinary shares					
c)	Price(s) and volume(s)	<table border="1"> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> <tr> <td>1.15 pence per Ordinary Share</td> <td>2,100,000 Ordinary Shares</td> </tr> </table>	Price(s)	Volume(s)	1.15 pence per Ordinary Share	2,100,000 Ordinary Shares	
Price(s)	Volume(s)						
1.15 pence per Ordinary Share	2,100,000 Ordinary Shares						
d)	Aggregated information: <input type="checkbox"/> Aggregated volume · Price	2,100,000 Ordinary Shares 1.15 pence per Ordinary Share					
e)	Dates of the transactions	27 March 2025					
f)	Place of the transactions	London					

Contacts

Genflow Biosciences

Dr Eric Leire, CEO
+32-477-495-881

Harbor Access

Jonathan Paterson, Investor Relations
+1 475 477 9401
Jonathan.Paterson@Harbor-access.com

Corporate Brokers

Capital Plus Partners Ltd

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through modulation of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASLD (Metabolic Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no current treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBBCGDXXXXDGUR

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.